NEFL and Alzheimer disease: These results indicate that plasma p-tau181 has better diagnostic and prognostic effects than other possible plasma biomarkers for AD (Aβ42/Aβ40, NFL, t-tau), which indicates that p-tau181 is likely to become the most clinically significant plasma biomarker (Giacomucci et al., 2022).